Viking Therapeutics Inc (VKTX) - Total Liabilities
Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has total liabilities worth $76.67 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Viking Therapeutics Inc (VKTX) cash flow conversion to assess how effectively this company generates cash.
Viking Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Viking Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check VKTX financial resilience to evaluate the company's liquid asset resilience ratio.
Viking Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Viking Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
China | CN¥11.19 Billion |
|
MERCARI INC. UNSP.ADR/1/2
F:6TP0
|
Germany | €503.91 Billion |
|
Micro-Star International Co Ltd
TW:2377
|
Taiwan | NT$66.35 Billion |
|
Flat Glass Group Co. Ltd
SHG:601865
|
China | CN¥19.62 Billion |
|
ATS CORP
TO:ATS
|
Canada | CA$2.70 Billion |
|
Proya Cosmetics Co Ltd Class A
SHG:603605
|
China | CN¥2.80 Billion |
|
Abercrombie & Fitch Company
NYSE:ANF
|
USA | $2.12 Billion |
|
Red Rock Resorts Inc
NASDAQ:RRR
|
USA | $3.98 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Viking Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Viking Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viking Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viking Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Viking Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $76.67 Million | +173.39% |
| 2024-12-31 | $28.04 Million | +39.72% |
| 2023-12-31 | $20.07 Million | -13.51% |
| 2022-12-31 | $23.21 Million | +164.38% |
| 2021-12-31 | $8.78 Million | -27.80% |
| 2020-12-31 | $12.16 Million | +70.35% |
| 2019-12-31 | $7.14 Million | +56.44% |
| 2018-12-31 | $4.56 Million | -47.30% |
| 2017-12-31 | $8.66 Million | +33.32% |
| 2016-12-31 | $6.49 Million | -3.30% |
| 2015-12-31 | $6.71 Million | -73.33% |
| 2014-12-31 | $25.17 Million | +5740.32% |
| 2013-12-31 | $431.00K | +308.86% |
| 2012-12-31 | $105.42K | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more